New Advancements from Ambion in Data Analysis for MicroRNA Profiling
News Feb 21, 2006
Ambion Services has announced the release of an expression profiling service specifically for microRNA analysis that surpasses any other offering currently in the market.
A growing body of evidence suggests that microRNAs could be useful in diagnosis and treatment for a range of diseases.
Based on technology from Ambion, expression profiles generated from this service are sensitive and representative of the microRNAs present in samples.
Ambion Services has further advanced this technology, developing proprietary algorithms for data normalization and scaling that are key to delivering meaningful expression information.
Ambion Services tailored their comprehensive data analysis algorithms and statistical approaches for microRNA profiling because many of the fundamental assumptions used for messengerRNA analysis do not apply.
According to Scott Hunicke-Smith, Ph.D., Vice President of Ambion Services, "One cannot rely on mRNA expression profiling experience when performing microRNA profiling data analysis."
"We have focused our development efforts, utilizing Ambion's extensive database of microRNA expression data, on the unique tools required for miRNA analysis."
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018